Search Results - "Jang, I J"

Refine Results
  1. 1

    Selective enhancement of optical nonlinearity in two-dimensional organic-inorganic lead iodide perovskites by Saouma, F. O., Stoumpos, C. C., Wong, J., Kanatzidis, M. G., Jang, J. I.

    Published in Nature communications (29-09-2017)
    “…Reducing the dimensionality of three-dimensional hybrid metal halide perovskites can improve their optoelectronic properties. Here, we show that the…”
    Get full text
    Journal Article
  2. 2

    Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium‐competitive acid blocker, in healthy male subjects by Sunwoo, J., Oh, J., Moon, S. J., Ji, S. C., Lee, S. H., Yu, K.‐S., Kim, H. S., Lee, A., Jang, I.‐J.

    Published in Alimentary pharmacology & therapeutics (01-07-2018)
    “…Summary Background A novel potassium‐competitive acid blocker, DWP14012, is in clinical development as a potential alternative to proton pump inhibitors for…”
    Get full text
    Journal Article
  3. 3

    Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance by Shin, K-H, Choi, M H, Lim, K S, Yu, K-S, Jang, I-J, Cho, J-Y

    Published in Clinical pharmacology and therapeutics (01-11-2013)
    “…This study aimed to evaluate endogenous metabolic markers of hepatic cytochrome P450 (CYP)3A activity in healthy subjects using a metabolomics approach…”
    Get full text
    Journal Article
  4. 4

    Targeted Next‐Generation Sequencing for Comprehensive Genetic Profiling of Pharmacogenes by Han, SM, Park, J, Lee, JH, Lee, SS, Kim, H, Han, H, Kim, Y, Yi, S, Cho, J‐Y, Jang, IJ, Lee, MG

    Published in Clinical pharmacology and therapeutics (01-03-2017)
    “…Phenotypic differences in drug responses have been associated with known pharmacogenomic loci, but many remain to be characterized. Therefore, we developed…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Pharmacokinetics and pharmacodynamics of intravenous dexmedetomidine in healthy Korean subjects by Lee, S., Kim, B.-H., Lim, K., Stalker, D., Wisemandle, W., Shin, S.-G., Jang, I.-J., Yu, K.-S.

    “…Summary What is known and Objective:  Dexmedetomidine is a selective alpha2‐adrenoreceptor agonist used for sedation in critically ill patients. The current…”
    Get full text
    Journal Article
  7. 7
  8. 8

    A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers by Yi, S., Lee, H., Jang, S. B., Byun, H. M., Yoon, S. H., Cho, J.‐Y., Jang, I.‐J., Yu, K.‐S.

    Published in Alimentary pharmacology & therapeutics (01-08-2017)
    “…Summary Background YH4808, a K+‐competitive acid blocker, is under clinical development for the treatment of acid‐related disorders, such as gastroesophageal…”
    Get full text
    Journal Article
  9. 9

    Near bandgap second-order nonlinear optical characteristics of MoS2 monolayer transferred on transparent substrates by Clark, D. J., Le, C. T., Senthilkumar, V., Ullah, F., Cho, H.-Y., Sim, Y., Seong, M.-J., Chung, K.-H., Kim, Y. S., Jang, J. I.

    Published in Applied physics letters (28-09-2015)
    “…We have investigated the second-order nonlinear optical (NLO) properties of CVD-grown MoS2 monolayer (ML) transferred onto transparent substrates such as fused…”
    Get full text
    Journal Article
  10. 10

    Aspirin Decreases Systemic Exposure to Clopidogrel Through Modulation of P-Glycoprotein But Does Not Alter Its Antithrombotic Activity by Oh, J, Shin, D, Lim, K S, Lee, S, Jung, K-H, Chu, K, Hong, K S, Shin, K-H, Cho, J-Y, Yoon, S H, Ji, S C, Yu, K-S, Lee, H, Jang, I-J

    Published in Clinical pharmacology and therapeutics (01-06-2014)
    “…Decreased oral clopidogrel absorption caused by induction of intestinal permeability glycoprotein (P‐gp) expression after aspirin administration was observed…”
    Get full text
    Journal Article
  11. 11

    Publisher Correction: Selective enhancement of optical nonlinearity in two-dimensional organic-inorganic lead iodide perovskites by Saouma, F. O., Stoumpos, C. C., Wong, J., Kanatzidis, M. G., Jang, J. I.

    Published in Nature communications (23-11-2017)
    “…In the PDF version of this article, Eq. 5 is missing all elements after the equals sign. The correct version of Eq. 5 is given below. The HTML version of the…”
    Get full text
    Journal Article
  12. 12

    Pharmacokinetic and Pharmacodynamic Interaction of Lorazepam and Valproic Acid in Relation to UGT2B7 Genetic Polymorphism in Healthy Subjects by Chung, J‐Y, Cho, J‐Y, Yu, K‐S, Kim, J‐R, Lim, KS, Sohn, D‐R, Shin, S‐G, Jang, IJ

    Published in Clinical pharmacology and therapeutics (01-04-2008)
    “…Pharmacokinetic and pharmacodynamic profiles of lorazepam and valproate were analyzed according to uridine 5′‐diphosphate‐glucuronosyltransferase (UGT)2B7…”
    Get full text
    Journal Article
  13. 13

    An Accelerator Mass Spectrometry‐Enabled Microtracer Study to Evaluate the First‐Pass Effect on the Absorption of YH4808 by Kim, A, Yu, B‐Y, Dueker, SR, Shin, K‐H, Kim, HS, Ahn, H, Cho, J‐Y, Yu, K‐S, Jang, IJ, Lee, H

    Published in Clinical pharmacology and therapeutics (01-09-2017)
    “…14C‐labeled YH4808, a novel potassium‐competitive acid blocker, was intravenously administered as a microtracer at 80 μg (11.8 kBq or 320 nCi) concomitantly…”
    Get full text
    Journal Article
  14. 14

    Pharmacodynamic comparison of two formulations of Acarbose 100-mg tablets by Lee, S., Chung, J. Y., Hong, K. S., Yang, S.-H., Byun, S.-Y., Lim, H.-S., Shin, S.-G., Jang, I.-J., Yu, K.-S.

    “…Summary What is known and Objective:  Acarbose, an α‐glycosidase inhibitor, is used to treat diabetic patients. Pharmacokinetic evaluation of acarbose is…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Frequency of CYP2C9 variant alleles, including CYP2C913 in a Korean population and effect on glimepiride pharmacokinetics by Lee, H. W., Lim, M.-s., Lee, J., Jegal, M.-Y., Kim, D.-W., Lee, W.-K., Jang, I.-J., Shin, J.-G., Yoon, Y.-R.

    “…Summary What is known and Objective:  Cytochrome P450 (CYP) 2C9 is a clinically important enzyme involved in the metabolism of many drugs commonly used in…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Exploration of Biomarkers for Amoxicillin/Clavulanate‐Induced Liver Injury: Multi‐Omics Approaches by Lee, J, Ji, SC, Kim, B, Yi, S, Shin, KH, Cho, JY, Lim, KS, Lee, SH, Yoon, SH, Chung, JY, Yu, KS, Park, HS, Kim, SH, Jang, IJ

    Published in Clinical and translational science (01-05-2017)
    “…To explore potential biomarkers for amoxicillin/clavulanate‐induced liver injury (AC‐DILI), we conducted a clinical trial in 32 healthy subjects based on…”
    Get full text
    Journal Article
  19. 19

    Prolonged Use of Aspirin Alters Human and Rat Intestinal Cells and Thereby Limits the Absorption of Clopidogrel by Jung, K‐H, Chu, K, Lee, S‐T, Yoon, H‐J, Chang, J‐Y, Nam, W‐S, Yoon, S‐H, Cho, J‐Y, Yu, K‐S, Jang, IJ, Kim, M, Lee, S K, Roh, J‐K

    Published in Clinical pharmacology and therapeutics (01-10-2011)
    “…Clopidogrel therapy to prevent atherothrombosis faces the challenge of reduced responsiveness. The absorption of clopidogrel is regulated by…”
    Get full text
    Journal Article
  20. 20

    Effect of multiple doses of fimasartan, an angiotensin II receptor antagonist, on the steady-state pharmacokinetics of digoxin in healthy volunteers by Yi, S, Kim, J W, Kim, T-E, Kim, J, Jun, Y K, Choi, J, Yoon, S H, Cho, J-Y, Song, S H, Shin, S-G, Jang, I-J, Yu, K-S

    “…Fimasartan (BR-A-657) is an angiotensin II receptor antagonist, recently approved as an antihypertensive agent. This study aimed to investigate whether…”
    Get full text
    Journal Article